Core Viewpoint - The company plans to conclude certain fundraising projects and permanently supplement working capital with the remaining funds, aiming to enhance the efficiency of fund utilization and improve operational effectiveness [1][2][3][4] Group 1: Fundraising Project Overview - As of June 16, 2025, the company has utilized 496.14 million yuan of the fundraising amount, with a remaining balance of 26.41 million yuan [1] - The company has experienced some idle funds due to the construction progress of fundraising projects, which require a certain period for investment [1] Group 2: Project Adjustments and Fund Allocation - The company has decided to terminate two sub-research projects under the "Linezolid and Voronazone Generic Project" while retaining the "Linezolid Sodium Chloride Injection" for continued development [2] - The remaining funds of 9.42 million yuan from the concluded project will be permanently allocated to supplement working capital for daily operations and business development [2][3] Group 3: Approval Process - The company's board of directors approved the proposal to conclude certain fundraising projects and allocate the remaining funds during a meeting on June 25, 2025, which will also be submitted for shareholder approval [3][4] - The supervisory board has also reviewed and approved the proposal, confirming that the project conclusion aligns with the actual construction status and does not harm the interests of shareholders [3][4] Group 4: Sponsor's Verification Opinion - The sponsor, Zhongshan Securities, has verified that the conclusion of the fundraising projects and the permanent allocation of remaining funds have been approved by the board and supervisory board, and are in compliance with relevant regulations [4]

Meeting Overview - The 2025 First Extraordinary General Meeting of Shareholders of Hangzhou Fulai Ente Co., Ltd. will be held on June 27, 2025, at 14:00 in Hangzhou, Zhejiang Province [4][5] - The meeting will adopt a combination of on-site and online voting methods [3][4] Shareholder Rights and Responsibilities - Shareholders and their proxies have the right to speak, inquire, and vote during the meeting [2][3] - Shareholders wishing to speak must register with the meeting service team upon signing in [2][3] Fundraising and Financial Overview - The company raised a total of RMB 107,388.14 million by issuing 33.34 million shares at RMB 32.21 per share, with a net amount of RMB 101,888.14 million after deducting fees [6][14] - As of May 31, 2025, the company has six fundraising accounts with a total balance of RMB 29,220,610.27 [7][15] Project Updates - The company plans to conclude the "Dye Intermediate Construction Project" with a total investment of RMB 9,306.60 million, which is 40.85% of the committed investment amount, resulting in a surplus of RMB 15,442.38 million [9][12] - The surplus funds will be permanently supplemented into the company's working capital for daily operations and business development [13][21] Project Changes - The company has proposed changes to certain fundraising projects, including the termination of the "Application R&D Center Construction Project" and the initiation of a new project with a total investment of RMB 6,226.00 million [18][20] - The decision to terminate the original project was based on the current adequacy of existing R&D facilities to meet operational needs [20][21]

Group 1 - The company held its 14th meeting of the 9th Supervisory Board on June 9, 2025, via remote voting, with all three supervisors participating, confirming the legality and validity of the meeting [1][2] - The Supervisory Board approved the proposal to adjust the investment scale of the "Guiyang Guanshanhu Tumor Hospital and Guiyang Shengjitang Diabetes Hospital Construction Project," concluding the project and permanently supplementing the remaining raised funds into working capital for daily operations, enhancing the efficiency of fund usage [1][2] - The decision-making process for the aforementioned matters complies with relevant laws and regulations, ensuring no harm to the company or minority shareholders' legitimate interests [1][2] Group 2 - The voting results for the proposal were unanimous, with 3 votes in favor, 0 against, and 0 abstentions, indicating strong support for the decision [2] - The proposal will be submitted for review at the company's upcoming shareholders' meeting [2] - Further details regarding the adjustment of the investment scale and the use of remaining funds will be published in the company's announcements in major financial newspapers and on the Shanghai Stock Exchange website [2]

Group 1 - The meeting of the fifth supervisory board of Jiangsu Wanlin Modern Logistics Co., Ltd. was held on May 15, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The supervisory board unanimously approved the proposal to conclude and terminate the fundraising investment project and permanently supplement the remaining raised funds into working capital, which aligns with the company's operational needs and long-term development [1][2] - The proposal will be submitted to the shareholders' meeting for further review [2]

Core Viewpoint - He Eye Hospital has decided to terminate the cross-border e-commerce project of Hainan He Eye Color Trading Co., Ltd. due to unsatisfactory performance and market conditions, aiming to enhance the efficiency of fund utilization and protect shareholder interests [1] Group 1 - The project had a total budgeted investment of 26 million yuan [1] - The decision was made during the third board and supervisory board meetings held on April 23, 2025 [1] - Remaining raised funds will be transferred to a special account for excess raised funds and the corresponding special account will be canceled [1]

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告……………第 3—15 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕226 号 浙江华康药业股份有限公司全体股东： 我们鉴证了后附的浙江华康药业股份有限公司（以下简称华康股份公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供华康股份公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为华康股份公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 中国·杭州 中国注册会计师： 二〇二五年二月二十六日 华康股份公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）和《上海证券交易所上市公司自律监管 指引第 1 号——规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的 规定编制《关于募集资金年度存放与使用情况 ...